Tyra Biosciences, Inc. (TYRA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tyra Biosciences, Inc. (TYRA) closed at USD 18.70 on 2026-10-14, a change of +28.4 % over the past year, with a market capitalization of USD 1.31B.

Tyra Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tyra Biosciences, Inc. key figures

Previous close

USD 18.70 (2026-10-14)

1-year change

+28.4 %

Market cap

USD 1.31B

Enterprise value

USD 787.89M

P/E ratio (trailing)

-7.77

P/E ratio (forward)

-6.87

EPS (trailing)

-2.45

EPS (forward)

-2.77

PEG ratio

n/a

Price to book

3.21

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.85

Employees

87

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tyra Biosciences, Inc. and compare it with other stocks.